secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pasithea Therapeutics Corp. (KTTA)
CIK:        0001841330
Form:       8-K
Filed at:   2021-12-21T23:59:59+00:00
Accession:  0001213900-21-066518
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Pasithea Therapeutics enters new CEO employment agreement with Tiago Reis Marques
--------------------------------------------------------------------------------

- Base salary $450,000; sign-on bonus $100,000 lump sum after Jan 1, 2022.
- Annual discretionary bonus up to 75% of base salary.
- Equity grants: 200,000 RSUs and 200,000 options vesting over 3 years (33% after 12 months, then quarterly).
- Severance: 12 months base salary if terminated without cause, subject to separation agreement.
- Agreement effective January 1, 2022; Board approved equity grants on Dec 20, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841330/000121390021066518/0001213900-21-066518-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841330/000121390021066518/ea152745-8k_pasithea.htm
  HTML page:      https://secwatch.observer/filing/0001213900-21-066518

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer